Wellbeing Digital Sciences Inc. - KONEF STOCK NEWS

Wellbeing Digital Sciences Inc. (OTC: KONEF) announced the award of an institution-wide cannabis research license to its subsidiary, KGK Science Inc., by Health Canada. This license significantly shortens timelines for cannabis research, allowing KGK to possess cannabis for R&D without needing project-specific licenses. CEO Najla Guthrie stated this will accelerate research programs and reduce time to market for clinical trials involving cannabis, enhancing their operational capabilities and impact in mental healthcare.

Wellbeing Digital Sciences Inc. (OTC: KONEF) announced positive results from a clinical trial on its bioflavonoid ingredient UP446, aimed at enhancing immune response post-influenza vaccination. Conducted by its subsidiary KGK Science Inc., the trial showed significant increases in immunoglobulin antibodies, particularly IgA and IgG, among participants taking UP446 compared to a placebo. This marks the first human study examining the effects of UP446, which is made from botanicals with antioxidant properties, on vaccine response.

Wellbeing Digital Sciences Inc. has announced that its subsidiary KGK Sciences submitted a clinical trial application for a Phase IIa study testing the efficacy of psilocybin in treating cognitive and behavioral symptoms associated with Fragile X Syndrome (FXS). The trial, sponsored by Nova Mentis Life Science Corp., will assess a 1.5 mg microdose of psilocybin and is expected to begin in early 2023 pending Health Canada's approval. This study marks a significant milestone as the first human trial using psilocybin for FXS.

Wellbeing Digital Sciences Inc. (OTC: KONEF) announced that its subsidiary, Mindscape Ketamine & Infusion Therapy, has successfully treated its 1,000th patient with IV Ketamine Therapy for treatment-resistant mood disorders and chronic pain conditions, achieved in under two years since acquisition. The clinic emphasizes cost-effective, tailored treatment, illustrating the increasing demand for ketamine therapy as a promising option for conditions like depression and PTSD. CEO Najla Guthrie highlighted the clinical advantages of this therapy, asserting its potential as a leading treatment.

Wellbeing Digital Sciences Inc. (OTC: KONEF) announces the appointment of Mohammad Sharifi to its Board of Directors effective November 22, 2022. Sharifi brings extensive experience in marketing and digital communications, having held senior roles at Telus Telecommunication. His expertise is expected to support Wellbeing's mission of enhancing mental health services through innovative clinical solutions, including psychedelic medicine and digital therapeutics. CEO Najla Guthrie underscores the importance of Sharifi's leadership during a pivotal growth phase for the company.

Wellbeing Digital Sciences Inc. (OTC: KONEF) has announced the resignation of directors James Henning and Steven Inglefield. Henning, a longstanding board member since the company's inception, contributed significantly to its growth. Inglefield, who also served as Chief Operating Officer, departs following the decision to divest IRP Health Ltd. to focus on its growth. CEO Najla Guthrie expressed gratitude for their contributions while emphasizing the need for fresh leadership as the company continues to develop innovative mental healthcare solutions.

Wellbeing Digital Sciences (OTC: KONEF, NEO: MEDI) announced that its subsidiary KGK Science will conduct a Phase II clinical trial to evaluate the effects of psilocybin on Fragile X syndrome. This marks the first research into psilocybin microdoses for improving behavioral and cognitive symptoms associated with the disorder. The trial, which will involve 10 participants, supports Nova Mentis’ drug development efforts under FDA Orphan Drug designation. Results are aimed at addressing significant unmet medical needs in treatment.

Wellbeing Digital Sciences Inc. (NEO: MEDI) announced that its subsidiary KGK Science Inc. successfully utilized Gefion Canada's GT4 technology to deliver CBD and THC through the skin in a recent study. This open-label study demonstrated effective transdermal delivery of cannabinoids, potentially offering steady-state concentrations without intoxication. Findings suggest the technology could benefit chronic conditions and vulnerable populations, particularly in pediatric treatment. The study's safety profile indicated no adverse effects on participants.

Wellbeing Digital Sciences Inc. (OTC: KONEF) announced that Andrew Charrette, Director of Regulatory Affairs at KGK Sciences, will participate in the Wonderland Miami Conference from November 3-5, 2022. This conference focuses on the psychedelic medicine sector, featuring industry leaders. Andrew is set to join the panel on 'The current state of clinical trial development' on November 5 at 9 a.m.. Wellbeing Digital aims to innovate in mental healthcare through evidence-based practices.